** Shares of CSPC Pharmaceutical Group 1093.HK jump 9.6% to HK$6.51, their highest levels since October 22
** Stock on course for a third straight session of gains, if current trend holds
** Stock marks the biggest intraday pct gain since April 1 and is third-biggest pct gainer in the Hong Kong's healthcare index .HSCIH, which rises 3%
** CSPC says its epidermal growth factor receptor antibody drug conjugate - CPO301 - has been granted the third Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced lung cancer
** CPO301 is undergoing clinical studies in China and the U.S. and the granting of Fast Track designation by the FDA will facilitate and expedite the development and registration of CPO301 in the U.S. and globally - CSPC
** Hang Seng Biotech Index .HSHKBIO rises 3.5%, Hang Seng Index .HSI climbs 1%
** YTD, stock up 32.6%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。